PPP3CB — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Faldaprevir (SCHEMBL222429)	1.00	1/20
Faldaprevir (SCHEMBL227410)	1.00	1/20
Faldaprevir (SCHEMBL7736941)	1.00	1/20
SCHEMBL7736946	0.93	1/20
SCHEMBL2633238	0.85	1/20
SCHEMBL3478879	0.83	1/20
SCHEMBL3369276	0.81	1/20
SCHEMBL8130336	0.75	1/20
SCHEMBL8136974	0.75	1/20
SCHEMBL3372659	0.75	1/20
SCHEMBL8251091	0.74	1/20
SCHEMBL3373234	0.73	1/20
SCHEMBL8251365	0.73	1/20
SCHEMBL8249995	0.73	1/20
SCHEMBL8251319	0.73	1/20
SCHEMBL1938185	0.71	1/20
SCHEMBL8249963	0.70	1/20
SCHEMBL8142087	0.69	1/20
SCHEMBL8250168	0.69	1/20
SCHEMBL8251578	0.69	1/20

Clinical trials — most relevant to PPP3CB by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis	PHASE4	COMPLETED
Lithium for Prevention of Cognitive Declining in Mood Illnesses	PHASE4	NOT_YET_RECRUITING
Strategies to Reduce Organic Muscle Atrophy in the Intensive Care Unit	PHASE2/PHASE3	WITHDRAWN
Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	ACTIVE_NOT_RECRUITING
Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients	PHASE3	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer	PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Open-label Study on Treatment of Primary Aldosteronism With Everolimus	PHASE2	COMPLETED
Salt-Sensitivity and Immunity Cell Activation	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Quantification of GADD34 Expression in RA	nan	COMPLETED
Effect of Esterogen Receptor Modulator on Gene in Bipolar Diseas	nan	NOT_YET_RECRUITING
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Ischemic Preconditioning to Prevent Acute Kidney Injury	nan	COMPLETED
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease	nan	COMPLETED
Transcutaneous Electrical Diaphragmatic Stimulation in Critically Ill Elderly Patients	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Pattern of Gene Expression in Adipose Tissue From Patients With Cushing Syndrome	nan	COMPLETED
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421	nan	COMPLETED
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PPP3CB binder may also engage these)

Protein	Name	Similarity
P48453	—	1.000	P48453 →
P20651	—	1.000	P20651 →
P63328	—	0.992	P63328 →
P48452	—	0.991	P48452 →
PPP3CA	Protein phosphatase 3 catalytic subunit alpha	0.987	landscape →
P63329	—	0.987	P63329 →
P48454	—	0.972	P48454 →
O54984	—	0.934	O54984 →
G3V9T7	—	0.934	G3V9T7 →
A5PJI5	—	0.933	A5PJI5 →
Q4W5Z4	—	0.933	Q4W5Z4 →
Q9DFS6	—	0.933	Q9DFS6 →
Q0IIZ2	—	0.932	Q0IIZ2 →
GET3	ATPase GET3	0.932	landscape →
P48597	—	0.932	P48597 →
G3MWR8	—	0.932	G3MWR8 →
KCNT1	Potassium channel subfamily T member 1	0.932	landscape →
Q7RTP6	—	0.931	Q7RTP6 →
Q8CJ19	—	0.930	Q8CJ19 →
P63073	—	0.930	P63073 →
Q503E1	—	0.930	Q503E1 →
Q5RIC0	—	0.930	Q5RIC0 →
Q9H9T3	—	0.930	Q9H9T3 →
Q9GKK5	—	0.929	Q9GKK5 →
Q9CWS4	—	0.929	Q9CWS4 →
P63074	—	0.929	P63074 →
Q2KJ61	—	0.929	Q2KJ61 →
Q5ZIH0	—	0.929	Q5ZIH0 →
Q8QFV0	—	0.928	Q8QFV0 →
Q5HZM6	—	0.928	Q5HZM6 →